Navigation Links
FDA Clears Volpara™ Breast Imaging Software for Automatic Calculation of Volumetric Breast Density
Date:11/18/2010

WELLINGTON, New Zealand, Nov. 18, 2010 /PRNewswire/ -- Offering radiologists a reliable and cost-effective tool to generate automatic volumetric breast density values, Volpara, Ltd., announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) for its Volpara™ breast imaging software. Volpara, a subsidiary of Matakina Technology, Limited of New Zealand, is responsible for commercial operations in the United States.

Automatically computing volumetric breast tissue density from screening mammograms, Volpara software assists radiologists by providing objective, automatic and robust measurement of volumetric breast tissue density.  Cleared for use with digital mammography systems, Volpara is currently available for Hologic and GE digital mammography systems with other systems undergoing validation.

Breast tissue density has not only been linked to an increased risk of breast cancer, it also decreases the sensitivity of the mammogram and thereby may impact early detection.  Several large studies have confirmed that as tissue density increases the accuracy of mammography decreases. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks the appearance of tumors (Boyd et al 2007, NEJM).  Since both dense breast tissue and cancer appear white on a mammogram, finding cancers can be analogous to looking for a snowball in a snow storm.

"Radiologists and imaging scientists have known for years the challenges that tissue density presents to mammography, but there haven't been the means to objectively and automatically quantify the actual amount of breast density from the screening mammogram," said Dr Ralph Highnam, CEO, Volpara, Ltd.  "Volpara will improve radiologists' understanding of breast composition and assist them in helping patients to make appropriate screening decisions."

Radiologists currently use the Breast Imaging Reporting and Data System (BI-RADS) system to classify density.  Developed by the American College of Radiology, the density assessment ranges from Category 1 (mostly fat) to Category 4 (extremely dense).  However, the density category assessment is subjective and varies widely among interpreting physicians, even those who are experienced.  Automated, objective, volumetric density assessments, consistently applied, has the potential both for establishing a new and important metric for mammography, and for allowing physicians to compare a patient's volumetric density from year to year.

"With the ability to objectively and accurately measure breast density, we can look at screening women with low and high densities differently rather than one size fits all universal screening programs. For example, it may be a good idea for women with very dense breasts to receive ultrasound or MRI in addition to mammography as part of regular screening. In the future, it may be possible by lowering breast density to reduce breast cancer risk. In this case, it would be helpful to monitor this process by tracking changes in breast density over time. An automated breast density system like Volpara provides quantitative reproducible measurements of breast density and could be useful for both of these purposes," said Prof. Martin J. Yaffe, PhD, of the Sunnybrook Health Sciences Centre in Toronto, and a renowned physicist responsible for pioneering work on quantitative breast imaging.

Volpara provides an easy to implement, objective volumetric assessment of breast tissue density. Using digital images and information captured in every mammographic exam, the system applies a state-of-the-art algorithm developed by some of the world's top imaging scientists using new developments in imaging physics. The robustness of the software provides quantitative reliability, allowing Volpara to be incorporated in both research and with clinical imaging protocols, which are becoming increasingly important as adjuvant imaging is being added to traditional screening mammography.

"Density has become a breast healthcare issue of increasing importance as Connecticut and at least seven other states have enacted or are considering density notification legislation. This was bolstered recently as Nancy Brinker, founder and CEO of Susan G. Komen for the Cure, expressed Komen's position that it should be regular practice for doctors to inform women of their breast density if their mammogram shows they have dense breast tissue, and that it is important for doctors to discuss with their patients with dense breasts what additional screening tools might be appropriate for them," said Gerald Kolb, vice president of Business Development for Volpara.

ABOUT VOLPARA

Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Limited is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand.  Volpara's founders and Board of Directors includes John Hood, PhD, former Vice Chancellor of the University of Oxford, UK, Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxford's most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.


'/>"/>
SOURCE Volpara, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain
2. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
3. FDA Clears AirStrip RPM for CRITICAL CARE & CARDIOLOGY Remote Patient Monitoring Solutions
4. FDA Clears Xlumenas NAVIX(TM) Access Device
5. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
6. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
7. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
8. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
9. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
10. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
11. FDA Clears a Test for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):